A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHAMPION
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 06 Oct 2017 Results (n=273) of a post hoc retrospective analysis developing and validating a prediction rule to identify patients unlikely to respond adequately to methotrexate using patient data from NCT00235820 and NCT00679731 trials published in the Journal of the American Academy of Dermatology
    • 08 Mar 2016 Pooled analysis (n=1692) of 4 trials (NCT00237887, NCT00235820, NCT00691964, NCT00710580) were presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 08 Mar 2016 Results of a pooled analysis (n=1372) from REVEAL and CHAMPION studies presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top